B+S Banksysteme Aktiengesellschaft (FRA:DTD2)

CTI BioPharma Cash Flow Statement

Financials in millions EUR. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Net Income	1.71	1.24	0.44	0.03	0.23	-0.27
Depreciation & Amortization	0.83	1.01	1.08	1.14	1.18	1.25
Other Amortization	0.16	0.16	0.17	0.36	0.37	0.36
Other Operating Activities	0.3	0.21	-0.22	0.39	-0.06	0.08
Change in Accounts Payable	0.19	0.16	-0.02	-0.01	-0.19	0.23
Change in Unearned Revenue	1.87	0.04	-0.35	0.29	0.08	-0.16
Change in Other Net Operating Assets	-3.83	0.02	-0.82	-0.7	-0.88	0.62
Operating Cash Flow	1.23	2.83	0.28	1.48	0.73	2.09
Operating Cash Flow Growth	-32.35%	907.83%	-80.97%	102.89%	-65.23%	-
Capital Expenditures	0.04	-0.01	-0.04	-0.04	-0.07	-0.22
Cash Acquisitions	-	-0.1	-0.1	-0.1	-0.1	0.58
Sale (Purchase) of Intangibles	-0.08	-0.08	-0.04	-	-0	-0.19
Other Investing Activities	0.05	0.04	0.03	0.02	0.01	0.02
Investing Cash Flow	0.01	-0.14	-0.15	-0.13	-0.17	0.19
Long-Term Debt Repaid	-	-1.09	-0.92	-1.15	-0.99	-1.12
Total Debt Repaid	-1	-1.09	-0.92	-1.15	-0.99	-1.12
Net Debt Issued (Repaid)	-1	-1.09	-0.92	-1.15	-0.99	-1.12
Other Financing Activities	-0.23	-0.24	-0.17	-0.16	-0.19	-0.22
Financing Cash Flow	-1.23	-1.33	-1.08	-1.31	-1.18	-1.34
Net Cash Flow	0.02	1.36	-0.96	0.04	-0.62	0.94
Free Cash Flow	1.27	2.83	0.24	1.43	0.65	1.88
Free Cash Flow Growth	-27.39%	1062.96%	-83.05%	119.27%	-65.16%	-
Free Cash Flow Margin	9.84%	22.23%	2.16%	12.94%	6.27%	19.06%
Free Cash Flow Per Share	0.21	0.46	0.04	0.23	0.10	0.30
Cash Interest Paid	0.23	0.24	0.17	0.16	0.19	0.22
Cash Income Tax Paid	0.05	0.04	0.06	0.04	0.03	0.02
Levered Free Cash Flow	1.16	2.29	0.21	1.88	0.96	1.48
Unlevered Free Cash Flow	1.3	2.44	0.32	1.98	1.07	1.62
Change in Net Working Capital	1.06	-0.25	1.01	-0.28	0.54	-0.55

Source: S&P Global Market Intelligence. Standard template. Financial Sources.